June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.

May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.

May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.

"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.

A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.

New research involving veterans highlights the need to monitor HIV-positive patients for cardiovascular risk.

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

Cardiorespiratory fitness and inflammation among sedentary people with HIV; helping patients increase physical activity; transwomen and metabolic syndrome; failed treatment of precancerous cervical lesions.

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

Debates about the role of abacavir (Ziagen, ABC) in the development of cardiovascular disease in persons living with HIV have raged for over a decade, and a kind of stalemate has been achieved between those who are and are not convinced of a link. Wh...